NL-OMON56670尚未招募不适用
Feasibility of skeletal muscle biopsy and near-infrared spectrometry in post-ICU patients: the Powerhouse feasibility study - Powerhouse Feasibility study
Ziekenhuisvoorzieningen Gelderse Vallei0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) >=18 years of age 2) Medical research council (MRC) sum score of at least 24
- •and less than 48 3) Serum haemoglobin of at least 5.0 mmol/L 4) BMI < 30 kg/m2
- •5) Admitted to an intensive care unit for at least 72 hours 6) exptected to be
- •discharged from the ICU within 48 hours 7) Written informed consent
排除标准
- •1) Known mitochondrial disease
- •2) Pre-existent muscle disease
- •3) Diabetes Mellitus
- •4) Life expectancy less than 6 months
- •5) Visibly high melanin content in the skin
- •6) Subcutaneous fat layer > 3cm covering the GA muscle (measured by
- •ultrasound)
- •7) Coagulopathy (i.e. platelet count; < 50 x10 9 cells/ml, INR > 2.0 or recent
- •treatment with therapeutic dosage of low molecular weight heparin)
- •8) Recent lower extremity surgery
- •9) Delirium (defined as a delirium observation screening scale (DOS) of at
- •least three)
- •10) Deemed incompetent to provide well-considered informed consent by the
- •treating physician
研究者
相似试验
已完成
不适用
The effect of anterior cruciate ligament injury on skeletal muscle function, contractile proteins and inflammatioAnterior cruciate ligament injuryMusculoskeletal - Other muscular and skeletal disordersACTRN12613000157774Victoria University12
进行中（未招募）
不适用
A study to evaluate muscle tissue, blood, urine and imaging assessments in patients with Late-Onset Pompe Disease treated with alglucosidase alfa.EUCTR2010-020611-36-NLGenzyme Europe B.V.15
进行中（未招募）
不适用
A study to evaluate muscle tissue, blood, urine and imaging assessments in patients with Late-Onset Pompe Disease treated with alglucosidase alfa.Pompe disease (acid alpha-glucosidase deficiency)MedDRA version: 14.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2010-020611-36-DEGenzyme Europe B.V.16
进行中（未招募）
不适用
A study to evaluate muscle tissue, blood, urine and imaging assessments in patients with Late-Onset Pompe Disease treated with alglucosidase alfa.Pompe disease (acid alpha-glucosidase deficiency)MedDRA version: 14.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-020611-36-GBGenzyme Europe B.V.15
终止
1 期
Muscle Malonyl Coa Biomarker Assay DevelopmentHealthy VolunteersNCT01003444Pfizer4